Legend Biotech Corp awarded CEO Zhang Ingrid 1,131,860 shares at $0 per share on September 15, 2026. For investors tracking executive ownership, the award leaves her with 1,131,860 Legend Biotech Corp shares, and the transaction represents about 100.0% of that resulting holding.
Key Highlights
- The filing lists SEC transaction code A for the transaction.
- Zhang Ingrid’s resulting Legend Biotech Corp holding was 1,131,860 shares.
- The transaction represented about 100.0% of her resulting shareholding.
Legend Biotech Corp (NASDAQ: LEGN) awarded Chief Executive Officer Zhang Ingrid 1,131,860 shares at $0 per share on September 15, 2026. Following the transaction, Zhang owned 1,131,860 shares.
Transaction Code A Appears in the Filing
The filing lists SEC transaction code A for this transaction. Zhang Ingrid is identified as Legend Biotech Corp’s Chief Executive Officer. Her resulting holding after the transaction was 1,131,860 shares, and the award represented about 100.0% of that holding. The stated value was $0 per share.
FAQs
Q: How many shares did Legend Biotech CEO Zhang Ingrid receive?
A: Zhang Ingrid received 1,131,860 Legend Biotech Corp shares. The shares were awarded at $0 per share on September 15, 2026.
Q: What percentage of Zhang Ingrid’s resulting holding did the award represent?
A: Zhang Ingrid’s 1,131,860-share award represented about 100.0% of her resulting holding, according to the filing. Following the transaction, she owned 1,131,860 Legend Biotech Corp shares.
Q: What does transaction code A mean for the Legend Biotech share award?
A: The filing lists SEC transaction code A for the transaction. It identifies Zhang Ingrid as Legend Biotech Corp’s Chief Executive Officer and states that she was awarded 1,131,860 shares.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.